Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
128 hedge funds and large institutions have $445M invested in Array Biopharma Inc in 2016 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 43 reducing their positions, and 17 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
27% more call options, than puts
Call options by funds: $3.25M | Put options by funds: $2.55M
16% more capital invested
Capital invested by funds: $382M → $445M (+$62.3M)
3% less funds holding
Funds holding: 132 → 128 (-4)
12% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 43
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$5.8M |
| 2 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$4.64M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$2.15M |
| 4 |
CEP
Chicago Equity Partners
Chicago,
Illinois
|
+$1.78M |
| 5 |
NC
Nexthera Capital
New York
|
+$1.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$6.96M |
| 2 |
AC
Armistice Capital
New York
|
-$5.9M |
| 3 |
VAM
Visium Asset Management
New York
|
-$4.5M |
| 4 |
State Street
Boston,
Massachusetts
|
-$4.07M |
| 5 |
DM
Deerfield Management
New York
|
-$3.81M |
ARRY Hedge Fund Activity: Q2 2016 in Review
128 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q2 2016, worth a combined $445M — up 16% from $382M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ARRY and 14 opened new positions — a net loss of 3 holders — while 43 trimmed existing stakes and 38 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $5.8M. The largest seller was Renaissance Technologies, cutting an estimated $6.96M.
- 128 institutional investors held Array Biopharma Inc (ARRY) as of Q2 2016, down from 132 in Q1 2016.
- Funds reported $445M of Array Biopharma Inc stock for Q2 2016, up 16% quarter-over-quarter.
- 14 funds opened new Array Biopharma Inc positions in Q2 2016 and 17 closed out, a net change of -3 holders.
- The largest Array Biopharma Inc buyer in Q2 2016 was Citadel Advisors, an estimated $5.8M added.
- The largest Array Biopharma Inc seller in Q2 2016 was Renaissance Technologies, an estimated $6.96M sold.
Based on aggregated 13F filings for Q2 2016.